Accuray Incorporated ( ARAY ) NASDAQ Global Select

Cena: 1.34 ( 0.37% )

Aktualizacja 07-21 22:00
NASDAQ Global Select
Branża: Medical - Specialties
Statystyki
Dywidendy
Rekomendacje
Wyceny
Wskaźniki
Analiza techniczna

Notowania:

Informacje o spółce:
Sektor: Zdrowie
Branża: Medical - Specialties
Zatrudnienie: 987
Giełda: NASDAQ Global Select
Ilość akcji w obrocie: 94.0566
Ilość akcji: Brak danych
Debiut giełdowy: 2007-02-08
WWW: https://www.accuray.com
CEO: Ms. Suzanne Winter M.B.A.
Adres: 1240 Deming Way
Siedziba: 53717-1954 Madison
ISIN: US0043971052
Opis firmy:

Accoray Incorporated Designs, opracowuje, produkuje i sprzedaje systemy radiochirurgia i radioterapii w leczeniu guzów w Stanach Zjednoczonych, Kanadzie, Ameryce Łacińskiej, Australii, Nowej Zelandii, Europie, Bliskim Wschodzie, Afryce, Japonii, Chinach i reszcie regionu Azji i Pacyfiku. Oferuje system Cyberknife, robotyczną stereotaktyczną radiochirurgię i stereotaktyczny układ radioterapii ciała stosowany w leczeniu pierwotnych i przerzutowych guzów poza mózgiem, w tym guzy na kręgosłupie lub w pobliżu piersi, nerki, wątroby, płuc, trzustki i prostaty. Firma zapewnia również system tomoterapii, w tym system Radixact, który umożliwia zintegrowane planowanie, dostarczanie i zarządzanie danymi leczenia radioterapii, umożliwiając klinicystom dostarczanie bardzo precyzyjnych metod leczenia około 50 pacjentów dziennie; system zarządzania danymi IDMS, w pełni zintegrowane systemy planowania i zarządzania danymi; oraz system planowania leczenia Accoray, systemy planowania i zarządzania danymi. Ponadto oferuje obsługę obsługi klienta po zawarciu, instalację, szkolenie i inne profesjonalne usługi. Firma przede wszystkim sprzedaje swoje produkty bezpośrednio klientom, w tym szpitale i samodzielne obiekty leczenia za pośrednictwem swojej organizacji sprzedaży, a także klientom za pośrednictwem agentów sprzedaży i organizacji zakupów grupowych w Stanach Zjednoczonych; oraz klientom bezpośrednio i za pośrednictwem dystrybutorów i agentów sprzedaży na arenie międzynarodowej. Accuray Incorporated został włączony w 1990 roku i ma siedzibę w Madison w stanie Wisconsin.

Wskaźniki finansowe
Kapitalizacja (USD) 138 037 420
Aktywa: 473 078 000
Cena: 1.34
Wskaźnik Altman Z-Score: -0.0
Słaby (wysokie ryzyko bankructwa)
Dywidenda: 0
P/E: -33.5
Ilość akcji w obrocie: 94%
Średni wolumen: 885 778
Ilość akcji 103 013 000
Wskaźniki finansowe
Przychody TTM 444 204 000
Zobowiązania: 427 855 000
Przedział 52 tyg.: 1.14 - 2.95
Piotroski F-Score: 2
Słaby (niska jakość finansowa)
EPS: -0.0
P/E branży: 17.0
Beta: 1.404
Raport okresowy: 2025-08-13
WWW: https://www.accuray.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Mr. Sandeep Chalke Senior Vice President & Chief Commercial Officer 826 177 1966
Mr. Jesse Chew Senior Vice President, Chief Legal Officer & Company Secretary 621 199 1981
Mr. Ali Pervaiz Senior Vice President & Chief Financial Officer, Interim Principal Accounting officer 601 119 1981
Mr. Michael Hoge Senior Vice President of Global Operations 540 115 1967
Ms. Suzanne Winter M.B.A. President, Chief Executive Officer & Director 1 021 519 1963
Mr. Juki Hozumi President & GM of Japan Region 0 0
Beth Kaplan Public Relations Director 0 0
Ms. Melanie Gebauer Vice President of Global Human Resources 0 0
Mr. Jim Dennison Senior Vice President of Global Regulatory, Quality & Product Development 0 0
Mr. John M. Dunn Vice President, Chief Information & Security Officer 0 0
Lista ETF z ekspozycją na akcje Accuray Incorporated
Symbol ETF Ilość akcji Wartość
IWM 2 732 188 3 661 132
IWO 854 489 1 145 015
FESM 599 077 832 717
VTWO 497 875 761 748
IWC 238 825 320 025
PRFZ 133 357 189 366
VTWG 79 625 121 826
IWN 68 734 92 104
RSSL 54 423 77 280
IWV 31 014 41 559
XSU.TO 18 251 33 399
UWM 10 265 14 576
URTY 8 521 12 099
VTHR 5 917 9 053
VTWV 4 021 6 152
HDG 127 180
PZW.TO 0 0
Wiadomości dla Accuray Incorporated
Tytuł Treść Źródło Aktualizacja Link
Here's Why You Should Hold Accuray Stock in Your Portfolio for Now ARAY continues to witness strength in its flagship, CyberKnife system, along with robust global performance. zacks.com 2025-05-15 15:10:10 Czytaj oryginał (ang.)
Accuray Showcases New Long-Term Data¹ on Benefits of 5 Session Radiotherapy Treatment for Men with Prostate Cancer at ESTRO 2025 More than 40 Clinical Studies Using Accuray Technology Presented at ESTRO 2025; Company Highlights Innovation and Educational Symposia MADISON, Wis. , May 7, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that new data presented at the European Society for Radiotherapy and Oncology (ESTRO) meeting reinforces the benefits of the company's CyberKnife ® System in the treatment of prostate cancer at multiple stages of the cancer journey. prnewswire.com 2025-05-07 11:35:00 Czytaj oryginał (ang.)
Accuray Announces First SRS/SBRT Patient Treatments in Austria With the CyberKnife® System Medical Team's Use of Accuray CyberComm™ Reduced Commissioning Time by Approximately 50 Percent*, Enabling Them to Initiate Patient Treatments Sooner MADISON, Wis. , May 5, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the CyberKnife® Center Salzburg is the first in Austria to treat patients with the CyberKnife ® System, expanding access to stereotactic radiosurgery (SRS) and ultra-hypofractionated stereotactic body radiation therapy (SBRT), treatment processes necessitating an extremely high degree of precision and accuracy. prnewswire.com 2025-05-05 20:10:00 Czytaj oryginał (ang.)
Accuray: Tariffs Are The Latest Obstacle For A Company That Has Struggled To Deliver (Rating Downgrade) Accuray has consistently struggled with execution, and now tariffs threaten to significantly impact the company's business in China - it's most promising growth driver. Recent Q3 results showed revenue growth but were overshadowed by weaker guidance and declining orders, particularly impacted by U.S.-China tariffs. The competition in China is intensifying, with local and global players ramping up efforts, challenging Accuray's ability to capitalize on a large market opportunity. seekingalpha.com 2025-05-03 06:52:36 Czytaj oryginał (ang.)
ARAY Stock Down Despite Q3 Earnings Beat Estimates, Revenues Up Y/Y Accuray reports solid fiscal third-quarter results, witnessing growth in Product & Services revenues and reduced operating expenses. zacks.com 2025-05-01 16:35:40 Czytaj oryginał (ang.)
Accuray Incorporated (ARAY) Q3 2025 Earnings Call Transcript Accuray Incorporated (NASDAQ:ARAY ) Q3 2025 Earnings Call April 30, 2025 4:30 PM ET Company Participants Jesse Chew - Chief Legal Officer Suzanne Winter - President and Chief Executive Officer Ali Pervaiz - Chief Financial Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Marie Thibault - BTIG Jason Wittes - ROTH Capital Operator Good day and welcome to the Accuray Third Quarter Fiscal 2025 Financial Results Conference Call. [Operator Instructions] Please note this event is being recorded. seekingalpha.com 2025-05-01 02:38:24 Czytaj oryginał (ang.)
Accuray (ARAY) Reports Q3 Loss, Tops Revenue Estimates Accuray (ARAY) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.06 per share a year ago. zacks.com 2025-04-30 22:50:27 Czytaj oryginał (ang.)
Accuray Reports Fiscal 2025 Third Quarter Financial Results MADISON, Wis. , April 30, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the third quarter ended March 31, 2025. prnewswire.com 2025-04-30 20:05:00 Czytaj oryginał (ang.)
Here's Why You Should Hold Accuray Stock in Your Portfolio for Now ARAY continues to witness strength in its flagship CyberKnife system, along with robust global performance. zacks.com 2025-04-07 12:45:33 Czytaj oryginał (ang.)
Accuray CyberKnife® Platform Featured in New Studies Showcasing its Benefits in Central Nervous System Tumors Presented at Radiosurgery Society Scientific Meeting Data Also Highlights Continued Clinical Advances Using the CyberKnife System That are Making High Quality Care an Option for People Who Previously Had Limited Choices MADISON, Wis. , April 3, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that new data on the clinical use of the CyberKnife ® System reinforce the device's broad-based radiation treatment capabilities for central nervous system (CNS) tumors. prnewswire.com 2025-04-03 11:35:00 Czytaj oryginał (ang.)
Accuray to Participate at 37th Annual Roth Conference MADISON, Wis. , March 12, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today announced its participation in the 37th Annual Roth Conference taking place on March 16 -18, 2025 in Dana Point, California. prnewswire.com 2025-03-12 09:30:00 Czytaj oryginał (ang.)
Here's Why You Should Hold Accuray Stock in Your Portfolio for Now ARAY continues to witness strength in its flagship CyberKnife system, along with robust global performance. zacks.com 2025-03-05 11:25:33 Czytaj oryginał (ang.)
ARAY Stock Up as Q2 Earnings & Revenues Beat Estimates, Margins Up Accuray delivers solid fiscal second-quarter results, witnessing growth in Product revenues and reduced operating expenses. zacks.com 2025-02-06 12:56:33 Czytaj oryginał (ang.)
Accuray Incorporated (ARAY) Q2 2025 Earnings Call Transcript Accuray Incorporated (NASDAQ:ARAY ) Q2 2025 Results Conference Call February 5, 2025 4:30 PM ET Company Participants Jesse Chew - Chief Legal Officer Suzanne Winter - President and Chief Executive Officer Ali Pervaiz - Chief Financial Officer Conference Call Participants Marie Thibault - BTIG Brooks O'Neil - Lake Street Capital Markets Operator Good day, and welcome to the Accuray Fiscal 2025 Second Quarter Financial Results Conference Call. All participants will be in a listen-only mode. seekingalpha.com 2025-02-06 00:03:02 Czytaj oryginał (ang.)
Accuray (ARAY) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates Although the revenue and EPS for Accuray (ARAY) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. zacks.com 2025-02-05 22:30:22 Czytaj oryginał (ang.)
Accuray (ARAY) Q2 Earnings and Revenues Top Estimates Accuray (ARAY) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to loss of $0.10 per share a year ago. zacks.com 2025-02-05 20:46:13 Czytaj oryginał (ang.)
Accuray Reports Strong Fiscal 2025 Second Quarter Financial Results & Raises Guidance MADISON, Wis., Feb. 5, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the second quarter ended December 31, 2024. prnewswire.com 2025-02-05 18:05:00 Czytaj oryginał (ang.)
Accuray Announces First 100 Patient Treatment Regimens Completed in China Using the Tomo® C Radiation Treatment Delivery System, a CNNC-Accuray Joint Venture Product MADISON, Wis. , Jan. 23, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Shandong Cancer Hospital and Institute has achieved a milestone with the completion of treatment for 100 patients using the Tomo® C Radiation Treatment Delivery System, a product built in China through the CNNC-Accuray joint venture. prnewswire.com 2025-01-23 09:35:00 Czytaj oryginał (ang.)
Accuray to Report Second Quarter Fiscal 2025 Financial Results on February 5, 2025 MADISON, Wis. , Jan. 22, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the second quarter of fiscal year 2025, ended December 31, 2024, during a conference call hosted by company management at 1:30 p.m. prnewswire.com 2025-01-22 18:05:00 Czytaj oryginał (ang.)
Leonel Peralta to Join Accuray as Chief Operations Officer MADISON, Wis. , Jan. 21, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Leonel Peralta is joining the company as Senior Vice President, Chief Operations Officer, effective February 3, 2025. prnewswire.com 2025-01-21 11:15:00 Czytaj oryginał (ang.)
Accuray (ARAY) Shows Fast-paced Momentum But Is Still a Bargain Stock Accuray (ARAY) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen. zacks.com 2025-01-20 11:55:19 Czytaj oryginał (ang.)
ARAY Stock Gains as China Approves Latest Radiation Therapy Solutions Accuray announces the approval of the Chinese NMPA for its latest radiation therapy solutions. zacks.com 2025-01-14 15:16:10 Czytaj oryginał (ang.)
Accuray Announces China National Medical Products Administration Approval of the Radixact® SynC™ and CyberKnife® S7™ Systems; Expands on the China Product Portfolio that Includes the Recently Approved Tomo® C System MADISON, Wis. , Jan. 13, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company's Radixact SynC™ System and CyberKnife® S7™ System have been approved by the Chinese National Medical Products Administration (NMPA). prnewswire.com 2025-01-13 17:00:00 Czytaj oryginał (ang.)
Here's Why You Should Add Accuray Stock to Your Portfolio Now ARAY's solid product demand and revenue growth raise optimism about the stock. zacks.com 2025-01-08 16:42:16 Czytaj oryginał (ang.)
Accuray - There's Value If Linac Sales Accelerate, But That's A Big 'If' Impressive revenue growth remains elusive for Accuray despite the potential in China, and there are ongoing challenges with profitability, competition, and market scale. The last quarter's results showed mixed performance, with better than expected revenue and a small guidance boost, but overall product sales were down and the backlog shrank modestly. Sustainability remains a key issue; China is growing nicely, but revenue in Japan weakened and the company has seen its installed base in the U.S. shrink, pressuring service revenue. seekingalpha.com 2025-01-07 12:52:22 Czytaj oryginał (ang.)
Here Is Why Bargain Hunters Would Love Fast-paced Mover Accuray (ARAY) If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Accuray (ARAY) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen. zacks.com 2025-01-03 12:01:58 Czytaj oryginał (ang.)
5 Beaten-Down MedTech Stocks Set to Rebound in 2025 Investors may want to take a closer look at discounted stocks, such as MCK, HAE, ARAY, LIVN and PBH, in the present market landscape. zacks.com 2024-12-30 11:25:28 Czytaj oryginał (ang.)
ARAY Stock Falls Despite Positive Data of CyberKnife in Treating BSM Accuray announces positive study data for its CyberKnife System in treating brainstem metastases. zacks.com 2024-12-19 12:20:31 Czytaj oryginał (ang.)
New Data Indicates the CyberKnife® System Can Provide a Safe and Effective Treatment Option to Control Brainstem Metastases, an Extremely Challenging Location to Treat Study Builds on Extensive Published Literature Highlighting the Benefits of the CyberKnife System in the Treatment of a Wide Range of Neurological Indications MADISON, Wis., Dec. 18, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today an international retrospective multicenter analysis found that radiosurgery (SRS) and fractionated stereotactic radiotherapy (FSRT), delivered with the CyberKnife® System, can provide an effective and time-saving treatment option for brainstem metastases (BSM). prnewswire.com 2024-12-18 09:35:00 Czytaj oryginał (ang.)
Looking for a Fast-paced Momentum Stock at a Bargain? Consider Accuray (ARAY) If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Accuray (ARAY) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen. zacks.com 2024-12-16 11:50:31 Czytaj oryginał (ang.)
Here's Why You Should Add Accuray Stock in Your Portfolio Now ARAY's solid product demand and revenue growth raise optimism about the stock. zacks.com 2024-12-10 14:11:19 Czytaj oryginał (ang.)
Accuray Incorporated Reports Inducement Award Under NASDAQ Listing Rules MADISON, Wis. , Nov. 26, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported, as required by NASDAQ Listing Rules, equity inducement awards to Mike Murphy, the company's new Vice President, Corporate Controller. prnewswire.com 2024-11-26 18:03:00 Czytaj oryginał (ang.)
Accuray Q1 Earnings Meet Estimates, Sales Beat, Gross Margin Shrinks ARAY's first-quarter fiscal 2025 earnings meet estimates. Both the top and bottom lines deteriorate year over year. zacks.com 2024-11-07 13:10:28 Czytaj oryginał (ang.)
Accuray Incorporated (ARAY) Q1 2025 Earnings Call Transcript Accuray Incorporated (ARAY) Q1 2025 Earnings Call Transcript seekingalpha.com 2024-11-07 00:29:37 Czytaj oryginał (ang.)
Accuray (ARAY) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates The headline numbers for Accuray (ARAY) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. zacks.com 2024-11-06 21:00:32 Czytaj oryginał (ang.)
Accuray (ARAY) Reports Q1 Loss, Tops Revenue Estimates Accuray (ARAY) came out with a quarterly loss of $0.04 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.03 per share a year ago. zacks.com 2024-11-06 20:26:28 Czytaj oryginał (ang.)
Accuray Reports Fiscal 2025 First Quarter Financial Results Strong Start to Fiscal Year, Raises 2025 Guidance MADISON, Wis. , Nov. 6, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the first quarter ended September 30, 2024. prnewswire.com 2024-11-06 18:05:00 Czytaj oryginał (ang.)
Accuray to Report First Quarter Fiscal 2025 Financial Results on November 6, 2024 MADISON, Wis., Oct. 23, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the first quarter of fiscal year 2025, ended September 30, 2024, during a conference call hosted by company management at 1:30 p.m. prnewswire.com 2024-10-23 20:05:00 Czytaj oryginał (ang.)
Accuray Appoints Michael Murphy as VP, Corporate Controller MADISON, Wis. , Oct. 21, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Michael Murphy, CPA has joined the company as Vice President, Corporate Controller. prnewswire.com 2024-10-21 20:05:00 Czytaj oryginał (ang.)
Here's Why You Should Retain Accuray Stock in Your Portfolio Now ARAY's solid product demand and revenue growth raise optimism about the stock. zacks.com 2024-10-17 16:15:48 Czytaj oryginał (ang.)
Accuray President and Chief Executive Officer Suzanne Winter Returns from Medical Leave of Absence MADISON, Wis. , Oct. 15, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced that, effective as of today, Suzanne Winter has returned from her temporary medical leave and assumed her full duties as President and Chief Executive Officer. prnewswire.com 2024-10-15 12:45:00 Czytaj oryginał (ang.)
Accuray Celebrates Opening of Genolier Innovation Hub in Switzerland, Initiation of CyberKnife® S7™ System Medical Professional Training Accuray is the first industry partner to open a facility at the Genolier Innovation Hub, created to provide opportunities for clinician-industry collaborations that can help accelerate improvements in patient care New Accuray CyberComm™ tool was used to significantly reduce the CyberKnife® S7™ System's commissioning time and enable product training in Genolier to begin more quickly MADISON, Wis. , Sept. 30, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the initiation of CyberKnife® S7™ System medical professional training at its education center located within the newly opened Genolier Innovation Hub, a fully-owned subsidiary of AEVIS VICTORIA SA, in Switzerland. prnewswire.com 2024-09-30 11:35:00 Czytaj oryginał (ang.)
Here's Why You Should Retain Accuray Stock in Your Portfolio Now ARAY's solid product demand and revenue growth raise optimism about the stock. zacks.com 2024-09-17 16:51:09 Czytaj oryginał (ang.)
ARAY Stock Up Following the Use of SGRT on Cancer Patients in Japan The latest adoption of Accuray's Radixact System and VitalHold package is likely to improve the care provided to cancer patients and their experience. zacks.com 2024-09-16 18:06:01 Czytaj oryginał (ang.)
Gifu Prefectural General Medical Center Achieves Milestone with Treatment of the First Cancer Patients in Japan Using the Accuray Radixact® System and VitalHold™ Solution The Technology Will Play an Important Role in the Hospital's Plan to Expand Patient Access to High Precision Radiation Therapy Treatments MADISON, Wis. , Sept. 10, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Gifu Prefectural General Medical Center is setting a new standard in cancer care in Japan as the first hospital in the country to treat patients with surface-guided radiation therapy (SGRT) using the company's Radixact ® Radiation Delivery System and VitalHold™* package. prnewswire.com 2024-09-10 21:30:00 Czytaj oryginał (ang.)